Radiofrequency ablation for hepatocellular carcinoma: The relationship between a new grading system for the ablative margin and clinical outcomes

Journal of Gastroenterology

Volumn 48, Issue 8, 2013, Pages 951-965

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Iguchi, Eriko ^a   Takeda, Haruhiko ^a   Matsuda, Fumihiro ^a   Nakajima, Jun ^a   Sakamoto, Azusa ^a   Hatamaru, Keiichi ^a   Saito, Sumio ^a   Nasu, Akihiro ^a   Kita, Ryuichi ^a   Kimura, Toru ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Ablative margin; Clinical outcome; Hepatocellular carcinoma; Radiofrequency ablation

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; IODINATED POPPYSEED OIL; SERUM ALBUMIN;

AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; THROMBOCYTE COUNT; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTRAST MEDIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETHIODIZED OIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884325109     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0690-0     Document Type: Article

References (58)

1. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol. 1996;167:759-68.
2. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis. Ann Surg. 2000;232:1694-702.
3. Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999;353:1676-7.
4. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-85.
5. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
6. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461-9.
7. Van de Wiele C. Radioembolization of hepatocellular carcinoma. Curr Drug Discov Technol. 2010;7(4):247-52.
8. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339-64.
9. Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):115-22.
10. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78(Suppl 1):113-24.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
12. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249:195-202.
13. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36.
14. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151-6.
15. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial or radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122-30.
16. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235-40.
17. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98(9):1210-24.
18. Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer. 1992;69:913-9.
19. Nagao T, Inoue S, Goto S, Mizuta T, Omori Y, Kawano N, et al. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg. 1987;205:33-40.
20. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. Initial treatment is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98-103.
21. Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2007;13:1003-9.
22. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40:1352-60.
23. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol. 2011;46(12):1418-26.
24. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002;225(1):143-9.
25. Sacks D, McClenny T, Cardella J, Lewis C. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14:S199-202.
26. Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011;53(1):136-47.
27. Liu CH, Arellano RS, Uppot RN, Samir AE, Gervais DA, Mueller PR. Radiofrequency ablation of hepatic tumors: effect of post-ablation margin on local tumor progression. Eur Radiol. 2010;20:877-85.
28. Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol. 2006;59:432-41.
29. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. Am J Roentgenol. 2010;195:758-65.
30. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201-9.
31. Murakami T, Ishimaru H, Sakamoto I, Uetani M, Matsuoka Y, Daikoku M, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intevent Radiol. 2007;30:696-704.
32. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188:480-8.
33. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer. 2001;92:126-35.
34. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol. 2005;43:458-64.
35. Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Zhang YQ, et al. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg Oncol. 2008;17(1):23-31.
36. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452-60.
37. Lautz HU, Selberg O, Körber J, Bürger M, Müller MJ. Protein-calorie malnutrition in liver cirrhosis. Clin Investig. 1992;70(6):478-86.
38. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol. 1994;21:317-35.
39. Ishikawa T, Michitaka I, Kamimura H, Higuchi K, Kubota T, Seki K, et al. Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology. 2009;56:1491-5.
40. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-54.
41. Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011;5(3):767-73.
42. Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44(9):991-9.
43. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299-306.
44. Shimomura S, Ikeda N, Saito M, Ishii A, Takashima T, Sakai Y, et al. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int. 2010;5(1):559-66.
45. Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007;72(Suppl 1):132-8.
46. Yao D, Jiang D, Huang Z, Lu J, Tao Q, Yu Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000;88(4):761-9.
47. Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23(9):787-93.
48. Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44(6):635-42.
49. Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, et al. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg. 2011;15(7):1173-81.
50. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994;106(6):1618-24.
51. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200-7.
52. Takayama T, Makuuchi M, Hasegawa K. Single HCC smaller than 2 cm: surgery or ablation?: surgeon's perspective. J Hepatobiliary Pancreat Sci. 2010;17(4):422-4.
53. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49(4):589-94.
54. Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, et al. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocelluar carcinoma. Eur J Radiol. 2012;81(10):2730-6.
55. Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, et al. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT. Br J Radiol. 1014;2012(85):745-52.
56. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569-77.
57. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocelluar carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252(3):905-13.
58. Wang W, Shi J, Xie WF. Transcatheter chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30(5):741-9.